Sight Sciences reported record quarterly revenue of $24.9 million, exceeding analyst expectations through strong execution in its dry eye and glaucoma franchises. The company significantly improved its financial position, reducing cash usage by 74% year-over-year while launching the OMNI Ultra Surgical System.
Key Highlights
- Record quarterly revenue of $24.9 million beat estimates by approximately 6%, representing 25% year-over-year growth.
- Interventional Dry Eye revenue surged to $3.9 million, a 45% sequential increase from the second quarter of 2026, following favorable MAC fee schedules.
- Raised full-year 2026 revenue guidance to a range of $92 million to $93 million, up from the previous midpoint of $90 million.
- Cash usage decreased to $2.4 million for the quarter, compared to $9.1 million in the same period last year, ending the period with $77.4 million in cash.